Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 175.58 USD 2.37% Market Closed
Market Cap: 310.3B USD
Have any thoughts about
Abbvie Inc?
Write Note

Abbvie Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Abbvie Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Abbvie Inc
NYSE:ABBV
Total Current Liabilities
$43.1B
CAGR 3-Years
15%
CAGR 5-Years
20%
CAGR 10-Years
21%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Liabilities
$11.7B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Total Current Liabilities
$20.3B
CAGR 3-Years
11%
CAGR 5-Years
14%
CAGR 10-Years
9%
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Total Current Liabilities
$1.2B
CAGR 3-Years
26%
CAGR 5-Years
28%
CAGR 10-Years
36%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Liabilities
$4B
CAGR 3-Years
28%
CAGR 5-Years
23%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Liabilities
$3.7B
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
24%
No Stocks Found

Abbvie Inc
Glance View

Market Cap
310.3B USD
Industry
Biotechnology
Economic Moat
Wide

AbbVie Inc., a leader in the pharmaceutical industry, emerged from its parent company Abbott Laboratories in 2013, with a mission centered around addressing some of the world’s most complex and serious diseases. At its core, AbbVie is a research-driven entity that leverages scientific innovation to develop advanced therapies. With a robust pipeline, the company focuses on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, and women's health. It has developed a diversified portfolio designed to tackle challenging health issues. The company devotes significant resources to research and development, fostering a culture that celebrates scientific discovery as a pathway to improving patient lives worldwide. Revenue generation for AbbVie is deeply intertwined with its treatment offerings, particularly its lineup of blockbuster drugs. The flagship product, Humira, an anti-inflammatory medication, has consistently stood as one of the top-selling drugs globally. Despite facing patent expirations for Humira, AbbVie has strategically navigated this challenge through its robust product pipeline, which includes promising medicines like Skyrizi and Rinvoq in immunology. The company also expanded its revenue potential significantly with the acquisition of Allergan in 2020, adding Botox and other products in aesthetics and eye care to its portfolio. The calculated diversification of revenue streams ensures AbbVie maintains a competitive edge, securing its position as a formidable player in the pharmaceutical industry.

ABBV Intrinsic Value
150.06 USD
Overvaluation 15%
Intrinsic Value
Price

See Also

What is Abbvie Inc's Total Current Liabilities?
Total Current Liabilities
43.1B USD

Based on the financial report for Sep 30, 2024, Abbvie Inc's Total Current Liabilities amounts to 43.1B USD.

What is Abbvie Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
21%

Over the last year, the Total Current Liabilities growth was 24%. The average annual Total Current Liabilities growth rates for Abbvie Inc have been 15% over the past three years , 20% over the past five years , and 21% over the past ten years .

Back to Top